Journal
Molecular Cancer Therapeutics
Publication Date
7-2-2024
Volume
23
Issue
7
First Page
924
Last Page
938
Document Type
Open Access Publication
DOI
10.1158/1535-7163.MCT-23-0471
Rights and Permissions
Meric-Bernstam F, Lloyd MW, Koc S, Evrard YA, McShane LM, Lewis MT, Evans KW, Li D, Rubinstein L, Welm A, Dean DA 2nd, Srivastava A, Grover JW, Ha MJ, Chen H, Huang X, Varadarajan K, Wang J, Roth JA, Welm B, Govinden R, Ding L, Kaochar S, Mitsiades N, Carvajal-Carmona L, Herylyn M, Davies MA, Shapiro GI, Fields R, Trevino JG, Harrell JC; NCI PDXNet Consortium; Doroshow JH, Chuang JH, Moscow JA. Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations. Mol Cancer Ther. 2024 Jul 2;23(7):924-938. doi: 10.1158/1535-7163.MCT-23-0471 This open access article is distributed under the Creative Commons AttributionNonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. ©2024 The Authors; Published by the American Association for Cancer Research
Recommended Citation
Meric-Bernstam, Funda; Govinden, Ramaswamy; Ding, Li; Fields, Ryan; and et al., "Assessment of patient-derived xenograft growth and antitumor activity: The NCI PDXNet consensus recommendations." Molecular Cancer Therapeutics. 23, 7. 924 - 938. (2024).
https://digitalcommons.wustl.edu/oa_4/3932
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
